Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement

被引:71
作者
Schiffmann, R
Rapkiewicz, A
Abu-Asab, M
Ries, M
Askari, H
Tsokos, M
Quezado, M
机构
[1] NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
关键词
Fabry disease; lysosomes; atherosclerosis; myocardial infarction; enzyme replacement therapy; glycolipids;
D O I
10.1007/s00428-005-0089-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We describe the postmortem findings of a 47-year-old man with Fabry disease, an X-linked glycolipid storage disorder, who was on enzyme replacement therapy with recombinant alpha-galactosidase A for more than 2 years. The patient had widespread atherosclerotic coronary artery disease that culminated in a massive acute myocardial infarction. Atherosclerotic lesions were seen in the right and left coronary systems, aorta, and the basilar artery. Typical Fabry cardiomyopathy and glomerular nephropathy were found. With the exception of vascular endothelial cells, extensive glycolipid storage deposits were seen in all vascular and nonvascular cells and organ systems. We conclude that, at least in this patient, repeated infusions with alpha-galactosidase A over a prolonged period did not appreciably clear storage material in cells other than vascular endothelial cells. These findings also illustrate accelerated atherosclerosis in susceptible patients with Fabry disease.
引用
收藏
页码:337 / 343
页数:7
相关论文
共 22 条
  • [1] Effect of genetic modifiers on cerebral lesions in Fabry disease
    Altarescu, G
    Moore, DF
    Schiffmann, R
    [J]. NEUROLOGY, 2005, 64 (12) : 2148 - 2150
  • [2] α-Galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency
    Bodary, PF
    Shen, YS
    Vargas, FB
    Bi, XM
    Ostenso, KA
    Gu, SF
    Shayman, JA
    Eitzman, DT
    [J]. CIRCULATION, 2005, 111 (05) : 629 - 632
  • [3] ENZYMATIC DEFECT IN FABRYS DISEASE - CERAMIDETRIHEXOSIDASE DEFICIENCY
    BRADY, RO
    GAL, AE
    BRADLEY, RM
    MARTENSS.E
    WARSHAW, AL
    LASTER, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (21) : 1163 - &
  • [4] Desnick RobertJ., 2001, The Metabolic and Molecular Bases of Inherited Disease, V8th, P3733, DOI DOI 10.1036/ommbid.181
  • [5] DUNCAN C, 1970, AUSTRALAS ANN MED, V19, P58
  • [6] Sequelae of storage in Fabry disease - pathology and comparison with other lysosomal storage diseases
    Elleder, M
    [J]. ACTA PAEDIATRICA, 2003, 92 : 46 - 53
  • [7] Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
    Eng, CM
    Guffon, N
    Wilcox, WR
    Germain, DP
    Lee, P
    Waldek, S
    Caplan, L
    Linthorst, GE
    Desnick, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) : 9 - 16
  • [8] FABRY DISEASE - AN UNUSUAL CAUSE OF SEVERE CORONARY-DISEASE IN A YOUNG MAN
    FISHER, EA
    DESNICK, RJ
    GORDON, RE
    ENG, CM
    GRIEPP, R
    GOLDMAN, ME
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 117 (03) : 221 - 223
  • [9] INVOLVEMENT OF DORSAL ROOT-GANGLIA IN FABRYS-DISEASE
    GADOTH, N
    SANDBANK, U
    [J]. JOURNAL OF MEDICAL GENETICS, 1983, 20 (04) : 309 - 312
  • [10] Electrocardiographic signs of hypertrophy in Fabry disease-associated hypertrophic cardiomyopathy
    Kampmann, C
    Wiethoff, CM
    Martin, C
    Wenzel, A
    Kampmann, R
    Whybra, C
    Miebach, E
    Beck, M
    [J]. ACTA PAEDIATRICA, 2002, 91 : 21 - 27